IP Library Patent Application 11281128
Patent Application
App. No. 11/281,128

Biodegradable vascular filter

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/281,128
Abstract

Novel enhanced products and processes for trapping emboli utilize self-expanding skeletons and biodegradable polymer systems, for example stent-like Nitinol® elements and PLGA, to address longstanding issues related to thrombus capture without deleterious impacts on the vasculature or other negative artifacts of the procedure by at least partial post-use dissolution in situ. Drug coating and elution technologies are included as would be known to those skilled in the art.

Claims (31)

1 . A biodegradable vascular filter system, which comprises, in combination:

a self-expanding apparatus which undergoes a phase change enabling it to move from a first, compacted position to a second, expanded position, operatively connected with;

a plurality of polymeric string-like members, which members expand from a slackened to a tensioned state in conjunction with the phase change of the associated apparatus;

wherein the system when implanted in at least one of a vessel and a body lumen and is effective for trapping thrombi traveling therethrough.

2 . The biodegradable vascular filter system of claim 1 the apparatus further comprising a plurality of strut members which are radially elongated in the first compacted position.

3 . The biodegradable vascular filter system of claim 2 , the apparatus further comprising an attachment between each of said polymeric string members and at least one of the plurality of strut members.

4 . The biodegradable vascular filter system of claim 3 , further comprising at least a supplemental restraining mechanism that maintain the self-expanding apparatus in the first position until a desired release time.

5 . The biodegradable vascular filter system of claim 3 , wherein the apparatus further comprises at least one shape memory alloy selected from the group consisting of Nitinol® and other biocompatible metals.

6 . The biodegradable vascular filter system of claim 4 , wherein the apparatus further comprises at least one polymer system selected from the group consisting of PLGA and other polymers which dissolve at a predetermined time.

7 . The biodegradable vascular filter system of claim 3 , wherein the apparatus further comprises Nitinol® struts and a plurality of string-like members comprised of PLGA.

8 . A process for mitigating insult and injury by thrombus comprising, in combination:

providing a vascular filter device further comprising a shape memory alloy skeleton operatively linked to a biodegradable polymer;

emplacing the vascular filter device at a desired location either upstream or downstream of at least one of a surgical and an interventional procedure site;

performing at least one of a surgical and an interventional procedure; and

leaving the vascular filter device in situ.

9 . The process of claim 8 , wherein the shape memory alloy is Nitinol® and the polymer system consists essentially of PLGA or other biodegradable polymera.

10 . A method for treating at least one of pulmonary embolism and a disease state characterized by generation of thrombus, which comprises the steps of:

operatively or interventionally disposing a filter in accordance with claim 7 within a desired vessel of a patient;

causing the filter to expand from a first compacted to a second expanded position;

capturing at least of emboli and thrombi for a desired period of time; and

having the web or matrix dissolve.

11 . A method for treating of claim 10 , wherein the vessel is the vena cava.

12 . (canceled)

13 . A method for treating of claim 10 , wherein the vessel is among the peripheral vasculature.

14 . The biodegradable vascular filter system of claim 7 , further comprising at least one drug eluting element.

15 . The biodegradable vascular filter system of claim 7 , wherein the central portion degrades in advance of the peripheral aspects of the system.

16 . The process of claim 8 , the providing step further comprising at least one of the filter device and biodegradable polymer being coated with and effective for eluting at least a drug.

17 . The biodegradable vascular filter system of claim 1 , further comprising at least one of bioabsorbable and bioresorbable material.

18 . The biodegradable vascular filter system of claim 1 , where the filter system is retrievable.

19 . The biodegradable vascular filter system of claim 7 , wherein the system remains operative within the body during a critical period and dissolves after the critical periods.

20 . The method of claim 13 , wherein at least a portion of the filter is at least one of coated with, and eluting of drugs.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2023
From: NOVATE MEDICAL LIMITED
To: BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED
Reel/Frame 065712/0956 →
RELEASE OF SECURITY INTEREST Recorded Sep 23, 2019
From: COVIDIEN GROUP S.À.R.L.; MS PACE LP
To: NOVATE MEDICAL LIMITED
Reel/Frame 050463/0026 →
RELEASE OF SECURITY INTEREST Recorded May 28, 2019
From: ACT 2001 VENTURE CAPITAL FUND GMBH & CO KG; ACT 2001 VENTURE CAPITAL FUND NO 1 LIMITED PARTNERSHIP; ACT 2001 VENTURE CAPITAL FUND NO 2 LIMITED PARTNERSHIP; ACT 2001 VENTURE CAPITAL FUND NO 2A LIMITED PARTNERSHIP; CO-INVESTMENT LIMITED PARTNERSHIP NO 2001 A5; FCPI CAPITAL INVEST PME 2015; FCPI CAPITAL INVEST PME 2016; INNOVATION PLURIEL N°4; COVIDIEN GROUP S.À.R.L.; MS PACE LP; SEROBA LIFE SCIENCES FUND II LIMITED PARTNERSHIP; GILSON, PAUL; CAP ASSOCIATES LIMITED
To: NOVATE MEDICAL LIMITED
Reel/Frame 049295/0138 →
SECURITY INTEREST Recorded Dec 22, 2017
From: NOVATE MEDICAL LIMITED
To: CAP ASSOCIATES LIMITED; GILSON, PAUL; ACT 2001 VENTURE CAPITAL FUND GMBH & CO KG; ACT 2001 VENTURE CAPITAL FUND NO 1 LIMITED PARTNERSHIP; ACT 2001 VENTURE CAPITAL FUND NO 2 LIMITED PARTNERSHIP; ACT 2001 VENTURE CAPITAL FUND NO 2A LIMITED PARTNERSHIP; CO-INVESTMENT LIMITED PARTNERSHIP NO 2001 A5; FCPI CAPITAL INVEST PME 2015; FCPI CAPITAL INVEST PME 2016; INNOVATION PLURIEL NO 4; COVIDIEN GROUP SARL; SEROBA LIFE SCIENCES FUND II LIMITED PARTNERSHIP
Reel/Frame 044469/0505 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2017
From: MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
To: COVIDIEN GROUP S.À R.L.
Reel/Frame 041718/0085 →
SECURITY INTEREST Recorded Nov 13, 2015
From: NOVATE MEDICAL LIMITED
To: MEDTRONIC VASCULAR GALWAY
Reel/Frame 037036/0901 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2006
From: SOSNOWSKI, STEPHEN A.; ROSENTHAL, DAVID, M.D.
To: NOVATE MEDICAL LTD.
Reel/Frame 018529/0027 →